Ropinirole

Evidence Level: L3

Predicted Indications: 10

Ropinirole

Pharmacist Assessment Report

Ropinirole: From Restless Legs Syndrome and Parkinson Disease to Attention Deficit-Hyperactivity Disorder

One-Sentence Summary

Ropinirole is a dopamine D2/D3 agonist, originally used to treat restless legs syndrome and Parkinson disease. The TxGNN model predicts it may be effective for attention deficit-hyperactivity disorder (ADHD), but no clinical trials are registered and the evidence consists of 8 publications, mostly reviews, a case report and indirect studies. One 2026 publication may be a randomized trial, but this needs verification.

Quick Overview

Item	Content
Original Indication	Restless legs syndrome, Parkinson disease
Predicted New Indication	Attention deficit-hyperactivity disorder
TxGNN Prediction Score	0.9999
Evidence Level	L3
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Ropinirole is a D2/D3 dopamine agonist. Detailed mechanism of action data is not available in the data compiled for this report, so this description rests on its known drug class.

ADHD involves dopaminergic dysregulation, and it frequently co-occurs with restless legs syndrome (RLS), an established ropinirole indication. A review (PMID 16218085) discusses this association and the possible value of treatments shared between the two conditions. This suggests a common dopaminergic and iron-metabolism pathway.

The direct clinical support is thin. A case report describes a 6-year-old with ADHD and RLS whose attention symptoms and sleep improved on ropinirole after limited benefit from methylphenidate. A 2026 publication appears to be an 8-week, double-blind, placebo-controlled trial of ropinirole added to methylphenidate in 66 children and adolescents aged 6-17. Its title is truncated in the data, so its design and results cannot be confirmed here.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
42640474	2026	Possible RCT (needs verification)	Eur Child Adolesc Psychiatry	8-week trial of ropinirole added to methylphenidate vs placebo in 66 outpatients aged 6-17 with ADHD; results not available in the data
16218085	2005	Review	Sleep	Reviews the association between RLS and ADHD and the potential for shared pharmacological treatment
18656214	2008	Review	Rev Neurol	Overview of restless legs syndrome (clinical features and prevalence)
15866437	2005	Case report	Pediatr Neurol	Child with ADHD and RLS improved in ADHD symptoms and sleep on ropinirole
34182128	2021	Preclinical	Pharmacol Res	D4 receptor variants and α2A adrenoceptor heteromerization, relevant to impulse-control disorders
24992083	2014	Clinical study (indirect)	Clin Neuropharmacol	Piribedil vs pramipexole and ropinirole on vigilance in Parkinson disease patients with daytime sleepiness
30950895	2019	Safety report	Cornea	Corneal edema in 3 patients exposed to dopaminergic agents
17483695	2007	Animal study	J Neuropathol Exp Neurol	Mouse model of RLS with A11 lesions and iron deprivation

India Market Information

Twenty valid single-ingredient registrations are listed. Approved indication text is not available in the records. Five main examples:

Authorization Number	Product Name	Dosage Form	Approved Indication
184311	Ropark 0.5 Tablet (Sun Pharmaceutical)	Strip of 10 tablets	Not specified
185061	Ropark XL 4 Tablet (Sun Pharmaceutical)	Strip of 10 extended-release tablets	Not specified
192786	Ropark 6mg Tablet XL (Sun Pharmaceutical)	Strip of 10 extended-release tablets	Not specified
187918	Ropitor 0.5mg Tablet (Torrent Pharmaceuticals)	Strip of 10 tablets	Not specified
195679	Ropikem 0.25mg Tablet (Chemo Healthcare)	Strip of 10 tablets	Not specified

All products are oral tablets, including extended-release forms.

Safety Considerations

Contraindications flagged in the knowledge graph (not label text): multiple system atrophy, postural orthostatic tachycardia syndrome, orthostatic hypotension, drug-induced dyskinesia, liver failure, psychotic disorders (including schizophreniform and schizoaffective disorder), mental disorder and hypotensive disorder.
Drug interactions: 167 interactions were identified. Moderate-level ones include morphine (including liposomal), cimetidine, dronabinol, nabilone, opium, metoclopramide and obeticholic acid.
Class-related concerns: Dopamine agonists are associated with impulse-control disorders (including gambling disorder), sleep attacks and corneal edema. These are especially relevant in children.

Please refer to the package insert for label warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN score is high, but the evidence is limited to a case report, reviews and one possible controlled trial whose design and results are unverified. No registered trials exist. Safety concerns in pediatric patients (impulse control, sleep attacks) are material.

To proceed, the following is needed:

Verify the full text, design and results of the 2026 publication (PMID 42640474)
Replication in adequately powered pediatric trials, with safety monitoring for impulse-control and sleep-related events
Package insert warnings and contraindications from the Indian regulator
Detailed mechanism of action data

Other Predicted Indications (Reference)

The other top-ranked predictions all carry a Hold recommendation. None has registered clinical trials.

Predicted Indication	TxGNN Score	Evidence Level	Note
Schizophrenia	0.9990	L4	Evidence is preclinical, case-based or indirect. D2/D3 agonism is opposite to standard antipsychotic action and may worsen psychosis. Psychotic disorders also appear among the knowledge-graph contraindications.
Faciodigitogenital syndrome	0.9998	L5	Model prediction only
Polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis	0.9992	L5	Model prediction only
Retinal dystrophy with or without extraocular anomalies	0.9991	L5	Model prediction only
Myopia X-linked	0.9990	L5	Model prediction only
Congenital disorder of glycosylation with defective fucosylation	0.9990	L5	Model prediction only
Atypical glycine encephalopathy	0.9989	L5	Model prediction only
Myopia 26, X-linked, female-limited	0.9988	L5	Model prediction only
Charcot-Marie-Tooth disease, demyelinating, type 1G	0.9988	L5	Model prediction only

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.